Does Cosentyx Cause Flare-Ups?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, does not typically cause disease flare-ups as a direct effect. Clinical trials show it reduces flares by targeting inflammation—patients on 300 mg doses saw 80-90% improvement in psoriasis symptoms at week 12, with sustained control over 52 weeks.[1] Real-world data aligns, with flare rates dropping after initiation.[2]
Why Might Someone Experience a Flare on Cosentyx?
Flares can occur due to indirect factors, not the drug itself:
- Paradoxical reactions: Rare cases (about 1-2%) involve new or worsening psoriasis-like symptoms, possibly from immune shifts. These often resolve after stopping treatment.[3]
- Infections or triggers: Upper respiratory infections, stress, or stopping other meds can provoke flares independently.[1]
- Dosing issues: Missing doses or inadequate response in non-responders (10-20% of patients) leads to breakthrough symptoms.[2]
How Common Are Flares Compared to Placebo?
In pivotal trials (e.g., ERASURE/SCULPTURE for psoriasis), flare rates were lower on Cosentyx (2-5%) than placebo (15-20%) at 12 weeks. Long-term extension studies report <5% annual flares with continuous dosing.[1][4] No evidence links Cosentyx to increased flares versus untreated states.
What Happens If Flares Persist?
Persistent flares signal potential non-response or complications—switching to another biologic (e.g., IL-23 inhibitors like Tremfya) resolves symptoms in 50-70% of cases.[5] Monitor with PASI scores; dermatologists often add topicals short-term. Report to FDA via MedWatch if suspected adverse event.
Patient Reports on Flares
Forums like Drugs.com and Reddit note occasional "initial flares" (first 4-8 weeks), often tied to injection site reactions or unrelated triggers, but most users (70%+) report fewer flares long-term. Paradoxical psoriasis affects <1%, per post-marketing surveillance.[3]
[1]: Novartis Cosentyx Prescribing Information, 2023. https://www.novartis.com/us-en/sites/novartis_us/files/cosentyx.pdf
[2]: Journal of the American Academy of Dermatology, "Real-world effectiveness of secukinumab," 2022. https://www.jaad.org/article/S0190-9622(22)00045-6/fulltext
[3]: FDA Adverse Event Reporting System (FAERS) data summary, 2023. https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-latest-quarterly-data-files
[4]: Lancet, "Secukinumab long-term safety," 2018. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32136-5/fulltext
[5]: British Journal of Dermatology, "Switching biologics in psoriasis," 2021. https://academic.oup.com/bjd/article/185/3/456/6321478